Suman Chowdhury

Suman Chowdhury
Rutgers New Jersey Medical School | UMDNJ · Department of Pharmacology and Physiology

PhD

About

18
Publications
6,410
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
145
Citations
Additional affiliations
October 2020 - present
Rutgers New Jersey Medical School
Position
  • PostDoc Position
February 2020 - September 2020
Guru Gobind Singh Indraprastha University
Position
  • Research Associate
August 2018 - February 2020
Guru Gobind Singh Indraprastha University
Position
  • Senior Researcher
Education
September 2015 - February 2020
July 2010 - May 2012
Jamia Hamdard University
Field of study
  • Biotechnology
July 2007 - May 2010
University of Delhi
Field of study
  • Botany

Publications

Publications (18)
Article
Full-text available
We have endeavored in this review to summarize our findings, which point to a systemic deficiency of ganglioside GM1 in Parkinson’s disease (PD) tissues. These include neuronal tissues well known to be involved in PD, such as substantia nigra of the brain and those of the peripheral nervous system, such as the colon and heart. Moreover, we included...
Article
Full-text available
Following our initial reports on subnormal levels of GM1 in the substantia nigra and occipital cortex of Parkinson’s disease (PD) patients, we have examined additional tissues from such patients and found these are also deficient in the ganglioside. These include innervated tissues intimately involved in PD pathology such as colon, heart and others...
Article
Full-text available
The aim of this study was to evaluate hypocholesterolemic potential of phytoconstituents of ethanolic seed extract of cumin (Cuminum cyminum L.) by assessments of interaction capabilities with 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoA) reductase through in vivo and in silico assessments along with screening of phytoconstituents of t...
Conference Paper
Full-text available
Alzheimer’s disease (AD) pathogenesis involves multiple pathological pathways, among different drug targets of AD,Glycogen synthase kinase 3 beta (GSK‐3β) is a well‐known therapeutic drug target. Identification of GSK‐3β inhibitors will also help in the treatment of other neurological disorders such as Parkinson’s disease, bipolar disorders, and tr...
Article
Full-text available
The fact that Parkinson’s disease (PD) pathologies are well advanced in most PD patients by the time of clinical elucidation attests to the importance of early diagnosis. Our attempt to achieve this has capitalized on our previous finding that GM1 ganglioside is expressed at subnormal levels in virtually all tissues of sporadic PD (sPD) patients in...
Article
Full-text available
Amyloidosis is the process of fibril formation responsible for causing several diseases in the human being that involve protein aggregation such as Alzheimer’s, Parkinson’s, Huntington’s disease, and type II diabetes. Natural phytocompounds such as curcumin shown promising anti-amyloidogenic activity. In the present study, selective phytocompounds...
Article
Full-text available
Abstract Alzheimer's disease (AD) is a neurodegenerative disorder, and multiple factors are involved in disease progression. This is why there is an urgent need to develop novel molecules with multi‐target‐directed ligands (MTDLs) potential. The current study explores the active phytoconstituents from traditionally used medicinal spices, namely pip...
Article
Full-text available
There is accumulating evidence showing that hyperglycemia conditions like diabetes possess a greater risk of impairment to the neuronal system because high glucose levels exacerbate oxidative stress, accumulation of amyloid-beta peptides, and mitochondrial dysfunction, and impair cognitive functions and cause neurodegeneration conditions like Alzhe...
Article
Background: Coronavirus disease 2019 (COVID-19) playing havoc across the globe caused 585,727 deaths and 13,616,593 confirmed cases so far as per World Health Organization data released till 17th July 2020. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) is responsible for causing this pandemic across different continents. It is not...
Article
Alzheimer's disease (AD), is a multifactorial neurodegenerative disorder characterized by memory loss and cognitive deficit. Various drug targets implicated in AD are β-amyloid (Aβ) peptides, cholinesterase enzymes, and free radicals. Plants derived phytoconstituents provides a vast pool of diverse compounds as a source of novel drugs. In view of t...
Article
Full-text available
Background: Alzheimer's disease (AD) is an irreversible neurodegenerative disease associated with memory loss and cognition deficit. At present, the drugs which are available in the markets only provide symptomatic relief to patients; there is no permanent cure for this disease. Several hypotheses have been proposed by various researchers, one of t...
Conference Paper
Full-text available
Alzheimer’s disease (AD) is a neurodegenerative disease, which is pathologically characterized by production and deposition of amyloid plaques. The plaques are formed by extracellular deposition of amyloid-b peptide (Ab). The b-secretase (b-site amyloid precursor protein cleaving enzyme, BACE1) is the principle enzyme responsible for the initiatory...
Article
Full-text available
Background Alzheimer’s disease (AD) is the most prevalent form of dementia and represents one of the highest unmet requirements in medicine today. There is shortage of novel molecules entering into market because of poor pharmacokinetic properties and safety issues. Drug repurposing offers an opportunity to reinvigorate the slowing drug discovery p...
Conference Paper
N-methyl-d-aspartate receptor (NMDAR) play key role in glutamatergic neurotramission which is critical for synaptic plasticity and survival of neurons. However, ‘slow excitotoxicity’ at post- synaptic neurons promotes gradual neurodegeneration as occurred in Alzheimer’s disease (AD). In view of this natural and synthetic compounds that act as antag...
Article
Full-text available
Depletion of acetylcholine in the central nervous system (CNS) is responsible for memory loss and cognition deficit. Enzyme acetylcholinesterase (AChE) is responsible for destruction of acetylcholine (Ach) in the brain. Many herbal plant extracts have been investigated for their potential use in the treatment of Alzheimer’s disease (AD) by inhibiti...
Article
Full-text available
This study identifies the efficacy of an ethyl acetate extract of Garcinia mangostana as a potent inhibitor of nitric oxide (NO) production. Crude extract in the range from 0.906µg/ml to 15.625µg/ml significantly decreased nitrite production in LPS-stimulated RAW 264.7 cells in vitro in a concentration dependent manner (11 μmol to 2.5 μmol) (p<0.01...
Article
Full-text available
Objective: According to cholinergic hypothesis, cholinesterase inhibitors are the only drugs approved for symptomatic treatment of Alzheimer's disease. The present study, evaluates the in-vitro butyrylcholinesterase (BChE) inhibitory activity and mode of inhibition by an aqueous extract of Cuminum cyminum using Ellman's method. Method: Ellman's ass...
Article
Full-text available
The cholinergic hypothesis of Alzheimer’s disease (AD) has provided the rationale for the current pharmacotherapy of this disease. Acetylcholinesterase (AChE) inhibitors are currently the only approved therapy for the symptomatic treatment of AD. The current drugs available in the market has shown various side effect which prompted scientist to sea...

Questions

Questions (9)
Question
Hello,
Are there any method available for examining auditory response(behaviour) in mice, which do not required electrode or any expensive equipment?
Project - BACE inhibitors
Question
Hello
I read  your research is on BACE inhibitors and was wondering if you can help me with. I am also working with beta secretase inhibition and planning to use sigma has BACE FRET Kit, but they have not given any information on the what concentration and volume of drug/ compound that should be used in the assay. If you have some insights, it will be helpful to me.
Question
Hello
I read  your research is on BACE inhibitors and was wondering if you can help me with. I am also working with beta secretase inhibition and planning to use sigma has BACE FRET Kit, but they have not given any information on the what concentration and volume of drug/ compound that should be used in the assay. If you have some insights, it will be helpful to me.
Project - BACE inhibition
Question
Hello
I read  your research is on BACE inhibitors and was wondering if you can help me with. I am also working with beta secretase inhibition and planning to use sigma has BACE FRET Kit, but they have not given any information on the what concentration and volume of drug/ compound that should be used in the assay. If you have some insights, it will be helpful to me.
Question
Hello
I read  your research is on BACE inhibitors and was wondering if you can help me with. I am also working with beta secretase inhibition and planning to use sigma has BACE FRET Kit, but they have not given any information on the what concentration and volume of drug/ compound that should be used in the assay. If you have some insights, it will be helpful to me.
Question
Hello
I read  your research is on BACE inhibitors and was wondering if you can help me with. I am also working with beta secretase inhibition and planning to use sigma has BACE FRET Kit, but they have not given any information on the what concentration and volume of drug/ compound that should be used in the assay. If you have some insights, it will be helpful to me.
Question
Hello
I read  your research is on BACE inhibitors and was wondering if you can help me with. I am also working with beta secretase inhibition and planning to use sigma has BACE FRET Kit, but they have not given any information on the what concentration and volume of drug/ compound that should be used in the assay. If you have some insights, it will be helpful to me.
Question
Hello
I read  your research is on BACE inhibitors and was wondering if you can help me with. I am also working with beta secretase inhibition and planning to use sigma has BACE FRET Kit, but they have not given any information on the what concentration and volume of drug/ compound that should be used in the assay. If you have some insights, it will be helpful to me.
Question
hello ,
I am working with beta amyloid with the objective to find antiaggregatory compound. Recently , i have performed Tht assay to measure inhibition by the compound. the problem I faced is that even after repeating my experiments i am getting the fluorescence in my test sample more than the control. All my compound are either alkaloid or polyphenols. I am not sure what is the reason for that. I have check the interference of the test compound but they do not seem to have their own fluorescence nor optically active. The control I am using is 44uM peptide in 1% DMSO.
It will be helpful if you could provide some insights.

Network

Cited By